The global Respiratory Disease Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

From a downstream perspective, Flu accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Respiratory Disease Vaccine leading manufacturers including AstraZeneca, Emergent BioSolutions Inc., GSK plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novavax, Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., SINOVAC, etc., dominate supply; the top five capture approximately % of global revenue, with AstraZeneca leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Respiratory Disease Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Respiratory Disease Vaccine Market Report

Report Metric	Details
Report Name	Respiratory Disease Vaccine Market
Segment by Type	Live Attenuated Inactivated Others
Segment by Application	Flu Pneumonia Others
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Emergent BioSolutions Inc., GSK plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novavax, Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., SINOVAC
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Respiratory Disease Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Respiratory Disease Vaccine Market report?

Ans: The main players in the Respiratory Disease Vaccine Market are AstraZeneca, Emergent BioSolutions Inc., GSK plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novavax, Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., SINOVAC

What are the Application segmentation covered in the Respiratory Disease Vaccine Market report?

Ans: The Applications covered in the Respiratory Disease Vaccine Market report are Flu, Pneumonia, Others

What are the Type segmentation covered in the Respiratory Disease Vaccine Market report?

Ans: The Types covered in the Respiratory Disease Vaccine Market report are Live Attenuated, Inactivated, Others

1 Study Coverage

1.1 Introduction to Respiratory Disease Vaccine: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Respiratory Disease Vaccine Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Live Attenuated

1.2.3 Inactivated

1.2.4 Others

1.3 Market Segmentation by Application

1.3.1 Global Respiratory Disease Vaccine Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Flu

1.3.3 Pneumonia

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Respiratory Disease Vaccine Revenue Estimates and Forecasts 2020-2031

2.2 Global Respiratory Disease Vaccine Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Respiratory Disease Vaccine Sales Estimates and Forecasts 2020-2031

2.4 Global Respiratory Disease Vaccine Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Respiratory Disease Vaccine Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Respiratory Disease Vaccine Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Live Attenuated Market Size by Manufacturers

3.5.2 Inactivated Market Size by Manufacturers

3.5.3 Others Market Size by Manufacturers

3.6 Global Respiratory Disease Vaccine Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Respiratory Disease Vaccine Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Respiratory Disease Vaccine Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Respiratory Disease Vaccine Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Respiratory Disease Vaccine Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Respiratory Disease Vaccine Sales and Revenue by Type (2020-2031)

6.4 North America Respiratory Disease Vaccine Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Respiratory Disease Vaccine Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Respiratory Disease Vaccine Sales and Revenue by Type (2020-2031)

7.4 Europe Respiratory Disease Vaccine Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Respiratory Disease Vaccine Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Respiratory Disease Vaccine Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Respiratory Disease Vaccine Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Respiratory Disease Vaccine Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Respiratory Disease Vaccine Sales and Revenue by Type (2020-2031)

9.4 Central and South America Respiratory Disease Vaccine Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Respiratory Disease Vaccine Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Respiratory Disease Vaccine Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Respiratory Disease Vaccine Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Respiratory Disease Vaccine Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 AstraZeneca

11.1.1 AstraZeneca Corporation Information

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.1.4 AstraZeneca Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 AstraZeneca Respiratory Disease Vaccine Sales by Product in 2024

11.1.6 AstraZeneca Respiratory Disease Vaccine Sales by Application in 2024

11.1.7 AstraZeneca Respiratory Disease Vaccine Sales by Geographic Area in 2024

11.1.8 AstraZeneca Respiratory Disease Vaccine SWOT Analysis

11.1.9 AstraZeneca Recent Developments

11.2 Emergent BioSolutions Inc.

11.2.1 Emergent BioSolutions Inc. Corporation Information

11.2.2 Emergent BioSolutions Inc. Business Overview

11.2.3 Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.2.4 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales by Product in 2024

11.2.6 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales by Application in 2024

11.2.7 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales by Geographic Area in 2024

11.2.8 Emergent BioSolutions Inc. Respiratory Disease Vaccine SWOT Analysis

11.2.9 Emergent BioSolutions Inc. Recent Developments

11.3 GSK plc.

11.3.1 GSK plc. Corporation Information

11.3.2 GSK plc. Business Overview

11.3.3 GSK plc. Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.3.4 GSK plc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 GSK plc. Respiratory Disease Vaccine Sales by Product in 2024

11.3.6 GSK plc. Respiratory Disease Vaccine Sales by Application in 2024

11.3.7 GSK plc. Respiratory Disease Vaccine Sales by Geographic Area in 2024

11.3.8 GSK plc. Respiratory Disease Vaccine SWOT Analysis

11.3.9 GSK plc. Recent Developments

11.4 Johnson & Johnson Services, Inc.

11.4.1 Johnson & Johnson Services, Inc. Corporation Information

11.4.2 Johnson & Johnson Services, Inc. Business Overview

11.4.3 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.4.4 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales by Product in 2024

11.4.6 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales by Application in 2024

11.4.7 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales by Geographic Area in 2024

11.4.8 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine SWOT Analysis

11.4.9 Johnson & Johnson Services, Inc. Recent Developments

11.5 Merck & Co., Inc.

11.5.1 Merck & Co., Inc. Corporation Information

11.5.2 Merck & Co., Inc. Business Overview

11.5.3 Merck & Co., Inc. Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.5.4 Merck & Co., Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Merck & Co., Inc. Respiratory Disease Vaccine Sales by Product in 2024

11.5.6 Merck & Co., Inc. Respiratory Disease Vaccine Sales by Application in 2024

11.5.7 Merck & Co., Inc. Respiratory Disease Vaccine Sales by Geographic Area in 2024

11.5.8 Merck & Co., Inc. Respiratory Disease Vaccine SWOT Analysis

11.5.9 Merck & Co., Inc. Recent Developments

11.6 Novavax

11.6.1 Novavax Corporation Information

11.6.2 Novavax Business Overview

11.6.3 Novavax Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.6.4 Novavax Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Novavax Recent Developments

11.7 Pfizer Inc.

11.7.1 Pfizer Inc. Corporation Information

11.7.2 Pfizer Inc. Business Overview

11.7.3 Pfizer Inc. Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.7.4 Pfizer Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Pfizer Inc. Recent Developments

11.8 Sanofi SA

11.8.1 Sanofi SA Corporation Information

11.8.2 Sanofi SA Business Overview

11.8.3 Sanofi SA Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.8.4 Sanofi SA Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Sanofi SA Recent Developments

11.9 Serum Institute of India Pvt. Ltd.

11.9.1 Serum Institute of India Pvt. Ltd. Corporation Information

11.9.2 Serum Institute of India Pvt. Ltd. Business Overview

11.9.3 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.9.4 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Serum Institute of India Pvt. Ltd. Recent Developments

11.10 SINOVAC

11.10.1 SINOVAC Corporation Information

11.10.2 SINOVAC Business Overview

11.10.3 SINOVAC Respiratory Disease Vaccine Product Models, Descriptions and Specifications

11.10.4 SINOVAC Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 SINOVAC Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Respiratory Disease Vaccine Industry Chain

12.2 Respiratory Disease Vaccine Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Respiratory Disease Vaccine Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Respiratory Disease Vaccine Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Respiratory Disease Vaccine Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Respiratory Disease Vaccine Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Astrazeneca plc

Emergent BioSolutions Inc

Serum Institute of India Pvt. Ltd

List of Tables

Table 1. Global Respiratory Disease Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Respiratory Disease Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Respiratory Disease Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Respiratory Disease Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Respiratory Disease Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Respiratory Disease Vaccine Sales by Region (2020-2025) & (K Units)

Table 8. Global Respiratory Disease Vaccine Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Respiratory Disease Vaccine Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Respiratory Disease Vaccine Sales Share by Manufacturers (2020-2025)

Table 12. Global Respiratory Disease Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Respiratory Disease Vaccine Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Respiratory Disease Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Disease Vaccine as of 2024)

Table 16. Global Respiratory Disease Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Respiratory Disease Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Respiratory Disease Vaccine Manufacturing Base and Headquarters

Table 19. Global Respiratory Disease Vaccine Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Respiratory Disease Vaccine Sales by Type (2020-2025) & (K Units)

Table 23. Global Respiratory Disease Vaccine Sales by Type (2026-2031) & (K Units)

Table 24. Global Respiratory Disease Vaccine Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Respiratory Disease Vaccine Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Respiratory Disease Vaccine ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Respiratory Disease Vaccine Sales by Application (2020-2025) & (K Units)

Table 29. Global Respiratory Disease Vaccine Sales by Application (2026-2031) & (K Units)

Table 30. Respiratory Disease Vaccine High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Respiratory Disease Vaccine Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Respiratory Disease Vaccine Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Respiratory Disease Vaccine ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Respiratory Disease Vaccine Growth Accelerators and Market Barriers

Table 37. North America Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Respiratory Disease Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Respiratory Disease Vaccine Growth Accelerators and Market Barriers

Table 40. Europe Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Respiratory Disease Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Respiratory Disease Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Respiratory Disease Vaccine Growth Accelerators and Market Barriers

Table 45. Southeast Asia Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Respiratory Disease Vaccine Investment Opportunities and Key Challenges

Table 47. Central and South America Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Respiratory Disease Vaccine Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. AstraZeneca Corporation Information

Table 51. AstraZeneca Description and Major Businesses

Table 52. AstraZeneca Product Models, Descriptions and Specifications

Table 53. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. AstraZeneca Sales Value Proportion by Product in 2024

Table 55. AstraZeneca Sales Value Proportion by Application in 2024

Table 56. AstraZeneca Sales Value Proportion by Geographic Area in 2024

Table 57. AstraZeneca Respiratory Disease Vaccine SWOT Analysis

Table 58. AstraZeneca Recent Developments

Table 59. Emergent BioSolutions Inc. Corporation Information

Table 60. Emergent BioSolutions Inc. Description and Major Businesses

Table 61. Emergent BioSolutions Inc. Product Models, Descriptions and Specifications

Table 62. Emergent BioSolutions Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Emergent BioSolutions Inc. Sales Value Proportion by Product in 2024

Table 64. Emergent BioSolutions Inc. Sales Value Proportion by Application in 2024

Table 65. Emergent BioSolutions Inc. Sales Value Proportion by Geographic Area in 2024

Table 66. Emergent BioSolutions Inc. Respiratory Disease Vaccine SWOT Analysis

Table 67. Emergent BioSolutions Inc. Recent Developments

Table 68. GSK plc. Corporation Information

Table 69. GSK plc. Description and Major Businesses

Table 70. GSK plc. Product Models, Descriptions and Specifications

Table 71. GSK plc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. GSK plc. Sales Value Proportion by Product in 2024

Table 73. GSK plc. Sales Value Proportion by Application in 2024

Table 74. GSK plc. Sales Value Proportion by Geographic Area in 2024

Table 75. GSK plc. Respiratory Disease Vaccine SWOT Analysis

Table 76. GSK plc. Recent Developments

Table 77. Johnson & Johnson Services, Inc. Corporation Information

Table 78. Johnson & Johnson Services, Inc. Description and Major Businesses

Table 79. Johnson & Johnson Services, Inc. Product Models, Descriptions and Specifications

Table 80. Johnson & Johnson Services, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Johnson & Johnson Services, Inc. Sales Value Proportion by Product in 2024

Table 82. Johnson & Johnson Services, Inc. Sales Value Proportion by Application in 2024

Table 83. Johnson & Johnson Services, Inc. Sales Value Proportion by Geographic Area in 2024

Table 84. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine SWOT Analysis

Table 85. Johnson & Johnson Services, Inc. Recent Developments

Table 86. Merck & Co., Inc. Corporation Information

Table 87. Merck & Co., Inc. Description and Major Businesses

Table 88. Merck & Co., Inc. Product Models, Descriptions and Specifications

Table 89. Merck & Co., Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Merck & Co., Inc. Sales Value Proportion by Product in 2024

Table 91. Merck & Co., Inc. Sales Value Proportion by Application in 2024

Table 92. Merck & Co., Inc. Sales Value Proportion by Geographic Area in 2024

Table 93. Merck & Co., Inc. Respiratory Disease Vaccine SWOT Analysis

Table 94. Merck & Co., Inc. Recent Developments

Table 95. Novavax Corporation Information

Table 96. Novavax Description and Major Businesses

Table 97. Novavax Product Models, Descriptions and Specifications

Table 98. Novavax Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Novavax Recent Developments

Table 100. Pfizer Inc. Corporation Information

Table 101. Pfizer Inc. Description and Major Businesses

Table 102. Pfizer Inc. Product Models, Descriptions and Specifications

Table 103. Pfizer Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Pfizer Inc. Recent Developments

Table 105. Sanofi SA Corporation Information

Table 106. Sanofi SA Description and Major Businesses

Table 107. Sanofi SA Product Models, Descriptions and Specifications

Table 108. Sanofi SA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Sanofi SA Recent Developments

Table 110. Serum Institute of India Pvt. Ltd. Corporation Information

Table 111. Serum Institute of India Pvt. Ltd. Description and Major Businesses

Table 112. Serum Institute of India Pvt. Ltd. Product Models, Descriptions and Specifications

Table 113. Serum Institute of India Pvt. Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Serum Institute of India Pvt. Ltd. Recent Developments

Table 115. SINOVAC Corporation Information

Table 116. SINOVAC Description and Major Businesses

Table 117. SINOVAC Product Models, Descriptions and Specifications

Table 118. SINOVAC Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. SINOVAC Recent Developments

Table 120. Key Raw Materials Distribution

Table 121. Raw Materials Key Suppliers

Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 123. Milestones in Production Technology Evolution

Table 124. Distributors List

Table 125. Market Trends and Market Evolution

Table 126. Market Drivers and Opportunities

Table 127. Market Challenges, Risks, and Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Respiratory Disease Vaccine Product Picture

Figure 2. Global Respiratory Disease Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Live Attenuated Product Picture

Figure 4. Inactivated Product Picture

Figure 5. Others Product Picture

Figure 6. Global Respiratory Disease Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Flu

Figure 8. Pneumonia

Figure 9. Others

Figure 10. Respiratory Disease Vaccine Report Years Considered

Figure 11. Global Respiratory Disease Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 13. Global Respiratory Disease Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 14. Global Respiratory Disease Vaccine Revenue Market Share by Region (2020-2031)

Figure 15. Global Respiratory Disease Vaccine Sales (2020-2031) & (K Units)

Figure 16. Global Respiratory Disease Vaccine Sales (CAGR) by Region (2020-2031) (K Units)

Figure 17. Global Respiratory Disease Vaccine Sales Market Share by Region (2020-2031)

Figure 18. Top 5 and Top 10 Manufacturers Respiratory Disease Vaccine Sales Volume Market Share in 2024

Figure 19. Global Respiratory Disease Vaccine Revenue Market Share Ranking (2024)

Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 21. Live Attenuated Revenue Market Share by Manufacturer in 2024

Figure 22. Inactivated Revenue Market Share by Manufacturer in 2024

Figure 23. Others Revenue Market Share by Manufacturer in 2024

Figure 24. Global Respiratory Disease Vaccine Sales Market Share by Type (2020-2031)

Figure 25. Global Respiratory Disease Vaccine Revenue Market Share by Type (2020-2031)

Figure 26. Global Respiratory Disease Vaccine Sales Market Share by Application (2020-2031)

Figure 27. Global Respiratory Disease Vaccine Revenue Market Share by Application (2020-2031)

Figure 28. North America Respiratory Disease Vaccine Sales YoY (2020-2031) & (K Units)

Figure 29. North America Respiratory Disease Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 30. North America Top 5 Manufacturers Respiratory Disease Vaccine Sales Revenue (US$ Million) in 2024

Figure 31. North America Respiratory Disease Vaccine Sales Volume (K Units) by Type (2020- 2031)

Figure 32. North America Respiratory Disease Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 33. North America Respiratory Disease Vaccine Sales Volume (K Units) by Application (2020-2031)

Figure 34. North America Respiratory Disease Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 35. US Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 36. Canada Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 37. Mexico Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 38. Europe Respiratory Disease Vaccine Sales YoY (2020-2031) & (K Units)

Figure 39. Europe Respiratory Disease Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 40. Europe Top 5 Manufacturers Respiratory Disease Vaccine Sales Revenue (US$ Million) in 2024

Figure 41. Europe Respiratory Disease Vaccine Sales Volume (K Units) by Type (2020-2031)

Figure 42. Europe Respiratory Disease Vaccine Sales Revenue (US$ Million) by Type (2020-2031)

Figure 43. Europe Respiratory Disease Vaccine Sales Volume (K Units) by Application (2020-2031)

Figure 44. Europe Respiratory Disease Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 45. Germany Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 46. France Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 47. U.K. Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 48. Italy Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 49. Russia Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Respiratory Disease Vaccine Sales YoY (2020-2031) & (K Units)

Figure 51. Asia-Pacific Respiratory Disease Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 52. Asia-Pacific Top 8 Manufacturers Respiratory Disease Vaccine Sales Revenue (US$ Million) in 2024

Figure 53. Asia-Pacific Respiratory Disease Vaccine Sales Volume (K Units) by Type (2020- 2031)

Figure 54. Asia-Pacific Respiratory Disease Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 55. Asia-Pacific Respiratory Disease Vaccine Sales Volume (K Units) by Application (2020-2031)

Figure 56. Asia-Pacific Respiratory Disease Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 57. Indonesia Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 58. Japan Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 59. South Korea Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 60. China Taiwan Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 61. India Respiratory Disease Vaccine Revenue (2020-2031) & (US$ Million)

Figure 62. Central and South America Respiratory Disease Vaccine Sales YoY (2020-2031) & (K Units)

Figure 63. Central and South America Respiratory Disease Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 64. Central and South America Top 5 Manufacturers Respiratory Disease Vaccine Sales Revenue (US$ Million) in 2024

Figure 65. Central and South America Respiratory Disease Vaccine Sales Volume (K Units) by Type (2021-2031)

Figure 66. Central and South America Respiratory Disease Vaccine Sales Revenue (US$ Million) by Type (2020-2031)

Figure 67. Central and South America Respiratory Disease Vaccine Sales Volume (K Units) by Application (2020-2031)

Figure 68. Central and South America Respiratory Disease Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 69. Brazil Respiratory Disease Vaccine Revenue (2020-2025) & (US$ Million)

Figure 70. Argentina Respiratory Disease Vaccine Revenue (2020-2025) & (US$ Million)

Figure 71. Middle East, and Africa Respiratory Disease Vaccine Sales YoY (2020-2031) & (K Units)

Figure 72. Middle East and Africa Respiratory Disease Vaccine Revenue YoY (2020-2031) & (US$ Million)

Figure 73. Middle East and Africa Top 5 Manufacturers Respiratory Disease Vaccine Sales Revenue (US$ Million) in 2024

Figure 74. Middle East and Africa Respiratory Disease Vaccine Sales Volume (K Units) by Type (2021-2031)

Figure 75. South America Respiratory Disease Vaccine Sales Revenue (US$ Million) by Type (2020-2031)

Figure 76. Middle East and Africa Respiratory Disease Vaccine Sales Volume (K Units) by Application (2020-2031)

Figure 77. Middle East and Africa Respiratory Disease Vaccine Sales Revenue (US$ Million) by Application (2020-2031)

Figure 78. GCC Countries Respiratory Disease Vaccine Revenue (2020-2025) & (US$ Million)

Figure 79. Turkey Respiratory Disease Vaccine Revenue (2020-2025) & (US$ Million)

Figure 80. Egypt Respiratory Disease Vaccine Revenue (2020-2025) & (US$ Million)

Figure 81. South Africa Respiratory Disease Vaccine Revenue (2020-2025) & (US$ Million)

Figure 82. Respiratory Disease Vaccine Industry Chain Mapping

Figure 83. Regional Respiratory Disease Vaccine Manufacturing Base Distribution (%)

Figure 84. Global Respiratory Disease Vaccine Production Market Share by Region (2020-2031)

Figure 85. Respiratory Disease Vaccine Production Process

Figure 86. Regional Respiratory Disease Vaccine Production Cost Structure

Figure 87. Channels of Distribution (Direct Vs Distribution)

Figure 88. Bottom-up and Top-down Approaches for This Report

Figure 89. Data Triangulation

Figure 90. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions